Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. operates under a multi-driven model focusing on "pharmaceuticals, finance, and health" [2][3] - The company adheres to the philosophy of "saving the world" and aims to provide safe and effective medicines [2][3] Financial Performance - As of September 30, 2023, total assets reached CNY 32.168 billion, an increase of CNY 0.995 billion (3.19%) from the beginning of the year [3] - Net assets attributable to shareholders increased to CNY 27.039 billion, up CNY 1.002 billion (3.85%) [3] - The company achieved a net profit of CNY 1.274 billion in the first three quarters of 2023, a year-on-year increase of CNY 0.394 billion (44.72%) [3] - The tax paid exceeded CNY 1 billion for several consecutive years, with a debt-to-asset ratio of 15.01% [3] Business Segments - The pharmaceutical segment includes traditional Chinese medicine, chemical drugs, and retail pharmacy [3] - The health segment produced over 200 health products, with 22 registered health food certificates and 76 filing certificates [3][4] - The financial investment segment holds significant shares in Guangfa Securities, constituting 20% of its total equity [4] Product Development and Sales - The company focuses on three core traditional Chinese medicine products: Anshen Bupai Liquid, Xiaoer Chaigui Fever Oral Liquid, and Xuefu Zhuyu Oral Liquid, all showing steady sales growth [5][6] - Anshen Bupai Liquid has achieved annual sales exceeding CNY 600 million, benefiting from a large target audience due to increasing stress-related sleep issues [6][7] - The company is actively engaged in R&D, with multiple projects in traditional Chinese medicine and chemical drugs, including 13 classic formulations and 10 secondary development projects [5][6] Investment Strategy - The company plans to increase its stake in Guangfa Securities by at least 1 million shares within the next 12 months [4] - It has invested in various funds focusing on biopharmaceuticals and medical research, enhancing its core competitiveness [4] Raw Material Supply - Jilin Aodong has established its own medicinal herb bases to ensure quality and stable supply of raw materials [7] - The company has received certification for high-quality ginseng and is committed to developing local medicinal resources [7] Convertible Bonds - The company aims to facilitate the conversion of its convertible bonds, currently priced at CNY 14.21 per share, and has conducted multiple share buybacks to boost investor confidence [7]
吉林敖东(000623) - 2024年1月11日投资者关系活动记录表